Core Viewpoint - The company, 开拓药业-B (09939.HK), has announced a conditional agreement to issue 30.4875 million shares at a subscription price of HKD 1.64 per share, representing a discount of approximately 15.03% from the last trading price of HKD 1.93 per share [1] Group 1: Subscription Agreement Details - The subscription is with 华圆管理咨询(香港)有限公司, which is wholly owned by 中新苏州工业园区创业投资有限公司 [1] - After the completion of the subscription, the subscriber and 原点创业投资 will collectively hold 49,115,740 shares, equivalent to 10.49% of the company's issued share capital and 9.85% of the enlarged share capital [1] - The shares being subscribed represent approximately 6.51% of the company's issued share capital as of the announcement date [1] Group 2: Financial Implications - The estimated net proceeds from the subscription, after deducting related expenses, are approximately HKD 49.78 million [1] - The company intends to use the net proceeds for general working capital and for the Phase III clinical trial of KX-826 [1]
开拓药业-B(09939.HK)拟折让15.03%发行3048.75万股 筹资4978万港元用于KX-826的III期临床试验